A Novel Approach to Justify Dissolution Differences in an Extended Release Drug Product using Physiologically Based Biopharmaceutics Modeling and Simulation

This publication has 31 references indexed in Scilit:

• Justification of Drug Product Dissolution Rate and Drug Substance Particle Size Specifications Based on Absorption PBPK Modeling for Lesinurad Immediate Release Tablets
  Molecular Pharmaceutics, 2016
• Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications
  The AAPS Journal, 2016
• Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms
  The AAPS Journal, 2016
• Dissolution Similarity Requirements: How Similar or Dissimilar Are the Global Regulatory Expectations?
  The AAPS Journal, 2015
• Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design Paradigm
  The AAPS Journal, 2015
• PBPK models for the prediction of in vivo performance of oral dosage forms
  European Journal of Pharmaceutical Sciences, 2014
• Dissolution Testing for Generic Drugs: An FDA Perspective
  The AAPS Journal, 2011
• Computer simulations using GastroPlus™ to justify a biowaiver for etoricoxib solid oral drug products
  European Journal of Pharmaceutics and Biopharmaceutics, 2009
• Impact of the intragastric location of extended release tablets on food interactions
  Journal of Controlled Release, 2005
• Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union
  European Journal of Pharmaceutical Sciences, 2002